迈向使用血浆蛋白质组学分析诊断疑似胆囊癌的精准医学策略:一项初步研究。
Towards precision medicine strategies using plasma proteomic profiling for suspected gallbladder cancer: A pilot study.
作者信息
Nouairia Ghada, Cornillet Martin, Jansson Hannes, Bergquist Annika, Sparrelid Ernesto
机构信息
Division of Hepatology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
出版信息
JHEP Rep. 2025 Feb 21;7(6):101365. doi: 10.1016/j.jhepr.2025.101365. eCollection 2025 Jun.
BACKGROUND & AIMS: Currently, preoperative diagnostic methods that can distinguish cancer from benign disease of the gallbladder are insufficient, and several surgical resections can be avoided if the pathology is known prior to surgery. This study aimed to assess whether preoperative plasma proteins can distinguish gallbladder cancer (GBC) from cholecystitis, with the main goal of identifying proteins for multivariate description of the postoperative diagnosis, before surgery.
METHODS
Samples from 82 individuals with suspected GBC who underwent bisegmentectomy and lymphadenectomy at Karolinska University Hospital between 2009 and 2020 were included in this retrospective, observational, single-center study. Preoperative plasma samples were analyzed using a 7,500 proteomics panel from SomaScan®. High-dimensional statistical methods including machine learning regularization, were used to analyze the data.
RESULTS
In our study, we identified and characterized a panel of 651 proteins that exhibited differential expression between GBC and cholecystitis. Through multivariate analysis, we demonstrated that circulating proteomics data provide valuable insights for diagnosing GBC before surgical intervention. Notably, we identified a subset of eight plasma proteins (PAHX, CD8A, HRG, CRIS2, Dynactin subunit 2, AT2A3, CSTN2, and DEPP) that effectively differentiated GBC from cholecystitis with a diagnostic accuracy of 94% when validated on a test set. These findings hold potential for clinical validation and could significantly aid in preoperative decision-making when GBC is suspected.
CONCLUSIONS
Our findings demonstrate that the preoperative assessment of plasma proteins can accurately differentiate cholecystitis from malignancy, supporting the potential development of a noninvasive test to assist preoperative decision-making when GBC is suspected.
IMPACT AND IMPLICATIONS
This study highlights the potential of plasma proteomic profiling to significantly improve the preoperative diagnostic accuracy of gallbladder cancer cholecystitis. Using machine learning models, we identified biologically relevant plasma proteins associated with the diagnosis of gall bladder cancer. A noninvasive preoperative test based on selected plasma proteins could potentially enhance clinical decision-making, reduce unnecessary surgeries, and mitigate the associated risks for patients with suspected GBC, marking a step forward in precision medicine.
背景与目的
目前,能够区分胆囊癌与良性胆囊疾病的术前诊断方法并不充分,如果术前已知病理情况,可避免一些手术切除。本研究旨在评估术前血浆蛋白是否能够区分胆囊癌(GBC)与胆囊炎,主要目标是在手术前确定用于术后诊断多变量描述的蛋白质。
方法
本回顾性、观察性、单中心研究纳入了2009年至2020年间在卡罗林斯卡大学医院接受双段切除术和淋巴结清扫术的82例疑似GBC患者的样本。术前血浆样本采用来自SomaScan®的7500蛋白质组学检测板进行分析。使用包括机器学习正则化在内的高维统计方法分析数据。
结果
在我们的研究中,我们鉴定并表征了一组651种在GBC和胆囊炎之间表现出差异表达的蛋白质。通过多变量分析,我们证明循环蛋白质组学数据为手术干预前诊断GBC提供了有价值的见解。值得注意的是,我们鉴定出了一个由八种血浆蛋白组成的子集(PAHX、CD8A、HRG、CRIS2、动力蛋白亚基2、AT2A3、CSTN2和DEPP),在测试集上进行验证时,其能够有效区分GBC与胆囊炎,诊断准确率为94%。这些发现具有临床验证的潜力,在怀疑患有GBC时可显著辅助术前决策。
结论
我们的研究结果表明,术前血浆蛋白评估能够准确区分胆囊炎与恶性肿瘤,支持开发一种无创检测方法,以辅助在怀疑患有GBC时进行术前决策。
影响与意义
本研究强调了血浆蛋白质组分析在显著提高胆囊癌与胆囊炎术前诊断准确性方面的潜力。通过机器学习模型,我们鉴定出了与胆囊癌诊断相关的具有生物学意义的血浆蛋白。基于选定血浆蛋白的无创术前检测可能会改善临床决策,减少不必要的手术,并降低疑似GBC患者的相关风险,这标志着精准医学向前迈进了一步。